IRF7 has been reported as the master regulator of type I IFN pathways and its involvement in IFN-β production has been well established.26,29 Higher expression of IRF7 and/or IFN-β is associated with a lower risk of bone metastasis in breast and prostate cancer,30,31 but the role of IRF7 in osteoclastogenesis, to our knowledge, has not been shown yet. Here, IRF7 is linked to prostate carcinoma.